Using comprehensive genomic profiling, we identified 59% of RAS/RAF wild-type MSS CRC concurrently harboured at least one oncogenic alteration in NF1, 13/20q, PI3K/mTOR, HRR, RTK pathways (Fig. 3a). The gene discussed is MTOR; the disease is colorectal carcinoma.